Miami (October 21, 2025) – The Bronchiectasis and NTM Association has accepted eight Care Center and 17 Clinical Associate Center sites in 14 states into the Bronchiectasis and NTM Care Center Network (CCN). The CCN includes 58 centers across the United States.
The CCN aims to facilitate access to specialized care and support for the hundreds of thousands of people with bronchiectasis and nontuberculous mycobacterial (NTM) lung disease.
“The prevalence of bronchiectasis and NTM lung disease continues to increase. Patients deserve access to high-quality, specialized care and resources,” said Doreen Addrizzo-Harris, M.D., Chair of the CCN Steering Committee. “The CCN’s innovative, nation-wide network will help us enhance care and improve quality of life for those living with these conditions, as well as accelerate progress toward a cure.”
Centers accepted into the CCN receive a designation of either a Bronchiectasis and NTM Care Center or a Bronchiectasis and NTM Clinical Associate Center, based on institutional resources and infrastructure. The requirements are established by the CCN’s Steering Committee, comprised of leading experts in the field.
The new Bronchiectasis and NTM Care Center sites are:
Baylor College of Medicine, Houston
Jane and Leonard Korman Respiratory Institute, Jefferson Health, Philadelphia
Montefiore Medical Center, Bronx, N.Y.
UConn Health, Farmington, Conn.
University of Iowa Health Care, Iowa City, Iowa
University of Texas Southwestern Medical Center, Dallas
University of Vermont Medical Center, Burlington, Vt.
Yale University, New Haven, Conn.
The new Bronchiectasis and NTM Clinical Associate Center sites are:
Baylor University Medical Center, Dallas
Beth Israel Deaconess Medical Center, Boston
Intermountain Medical Center Schmidt Chest Clinic, Murray, Utah
Keck Medicine of USC, Los Angeles
Mayo Clinic Arizona, Phoenix
Mayo Clinic Florida, Jacksonville, Fla.
Providence Medical Group, Spokane, Wash.
Pulmonary Sleep Center of the Valley, Weslaco, Texas
Santa Barbara Cottage Hospital, Santa Barbara, Calif.
Temple Lung Center, Philadelphia
UC Davis Medical Center, Sacramento, Calif.
UCI Health, Orange, Calif.
University of Cincinnati, UC Medical Center, Cincinnati
University of South Florida, Tampa, Fla.
VCU Health, Richmond, Va.
Westchester Medical Center, Valhalla, N.Y.
Zuckerberg San Francisco General Hospital, San Francisco
The Bronchiectasis and NTM Care Center Network is generously supported by Insmed Incorporated as a Founding Sponsor and Boehringer Ingelheim.
For more information about the Bronchiectasis and NTM Care Center Network, visit www.bronchandntm.org .
###
About Bronchiectasis and NTM Lung Disease
Bronchiectasis is a chronic lung disease characterized by enlarged airways that are thickened and/or scarred. These permanently widened airways lead to a buildup of mucus and impaired clearance of bacteria from the lungs. Between 340,000 and 522,000 adults are receiving treatment in the U.S.
Nontuberculous mycobacterial (NTM) lung disease is a chronic respiratory condition caused by certain types of mycobacteria commonly found in the environment, such as in soil and water. NTM lung disease predominantly affects individuals with compromised immune systems or pre-existing lung conditions, such as bronchiectasis and chronic obstructive pulmonary disease (COPD). NTM lung disease affects tens of thousands of individuals in the U.S. with rates of infection on the rise.
About the Bronchiectasis and NTM Association
The Bronchiectasis and NTM Association is a nonprofit organization whose mission is to improve the lives of people with bronchiectasis, nontuberculous mycobacterial lung (NTM) disease, or both conditions. The Association accomplishes this by providing education, supporting advocacy, furthering research, and advancing high-quality, specialized care. For more information, visit www.bronchandntm.org .